American Bio Medica Corporation (ABMC)

Market Cap	48.00
Revenue (ttm)	726.00K -63.8%
Net Income	850.00K
EPS	0.02
Shares Out	48.10M
PE Ratio	0.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	17,037
Open	0.0000
Previous Close	0.0001
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.0002
Beta	-18.86
RSI	45.80
Earnings Date	n/a

About American Bio Medica

American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detec...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1986
• Employees: 20
• Stock Exchange: OTCMKTS
• Ticker Symbol: ABMC

Financial Performance

In 2022, American Bio Medica's revenue was $913,000, a decrease of -58.84% compared to the previous year's $2.22 million. Losses were -$1.41 million, 204.5% more than in 2021.